TMCnet News
Global Mucopolysaccharidosis (MPS) Treatment Market to Surpass US$ 3,014.9 Million by 2027, Says Coherent Market Insights (CMI)According to Coherent Market Insights, the global mucopolysaccharidosis (MPS) treatment market is estimated to be valued at US$ 1,566.5 million in 2020 and is expected to exhibit a CAGR of 9.8% over the forecast period (2020-2027). Key Trends and Analysis of the Global Mucopolysaccharidosis (MPS) Treatment Market: Key trends in the global mucopolysaccharidosis (MPS) treatment market include increasing research and development activities by market players, increasing product launches and approvals, and increasing merger, acquisitions, and partnerships by market players. For instance, on April 3, 2019, Regenxbio Inc. initiated a clinical trial study to evaluate RGX-111, a gene therapy, which is intended to deliver a functional copy of the a-L-iduronidase (IDUA) gene to the central nervous system. This is a safety and dose ranging study to determine whether RGX-111 is safe and tolerated by patients with MPS I. The study is estimated to be completed in July 2023. Market players are focusing on launching new therapeutics for the treatment of rare diseases, which is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market over the forecast period. In June 2019, BioMarin Pharmaceutical Inc. received approval for its Vimizim (elosulfase alfa) from National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition. Furthermore, key players in the market are focused on adopting various inorganic strategies such as mergers and partnerships to enhance their product portfolio. For instance, in April 2020, JCR Pharmaceuticals Co Ltd. acquired ArmaGen, Inc., a biopharmaceutical company based in San Diego, California. As a result of this acquisition, JCR Pharmaceuticals acquired all the intellectual property associated with a broad disease spectrum, including lysosomal storage disorders (LSDs) products. Therefore, this acquisition will bring innovative medicines for the patients suffering from mucopolysaccharidosis and oter LSDs. Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4184 Key Market Takeaways: The global mucopolysaccharidosis (MPS) treatment market is expected to exhibit a CAGR of 9.8% over the forecast period. This is owing to increasing product approvals by regulatory authorities. For instance, in August 2018, Ultragenyx Pharmaceuticals Inc. received European Commission approval for the marketing of Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII. Mepsevii is approved for use in all 28 European countries. Among region, North America is expected to hold dominant position in the global mucopolysaccharidosis (MPS) treatment market over the forecast period, owing to approval of novel therapies in late-phase clinical trials and increasing R&D activities by key players in the region. For instance, in June 2019, Denali Therapeutics Inc. received the U.S FDA's Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation for its pipeline drug candidate DNL310, which is being evaluated for the treatment of mucopolysaccharidosis II ('MPS II' or Hunter Syndrome). Competitive Landscape: Key players operating in the global mucopolysaccharidosis (MPS) treatment market include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4184 Market Segmentation:
About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005480/en/ |
